ERBB2 and cancer: The highest proportion of the patients with a confirmed pCR was found for triple negative breast cancer (TNBC) (62.5%); non-luminal HER2-positive (52.6%) cancer subtypes (<i>p</i> = 0.0003); and in the G3 group (50%; <i>p</i> = 0.0078).